急性心肌梗死溶栓后联合使用阿司匹林及氯吡格雷的疗效和安全性研究被引量：10

下载PDF

导出

摘要目的探讨急性心肌梗死患者接受标准剂量尿激酶溶栓后给予阿司匹林及氯吡格雷的疗效和安全性。方法我院住院的急性心肌梗死患者52例,因各种原因未行急诊PCI(经皮冠状动脉介入治疗)患者,同时符合溶栓条件,且发病时间在6 h内,均给予尿激酶溶栓后随机分为2组:治疗组26例,给予阿司匹林0.3 g,1次/d,7d后改为0.1 g,1次/d,同时给予氯吡格雷负荷量300mg,然后75 mg1次/d;对照组26例,给予阿司匹林0.3 g,1次/d,7 d后改为0.1 g,1次/d,治疗观察30 d。比较两组间心绞痛发作次数及发作平均持续时间、再梗发生率、病死率及不良反应的发生情况。结果(1)治疗组心绞痛发作次数及发作平均持续时间较对照组明显降低(P<0.05);(2)再梗发生率、病死率较对照组均明显下降(P<0.05)。结论强化抗血小板治疗可改善急性心肌梗死患者溶栓后的临床症状和预后,提高生活质量,减少严重出血等不良事件。

作者杨平

机构地区广西柳州市肿瘤医院内科

出处《内科》 2009年第5期707-709,共3页 Internal Medicine

关键词急性心肌梗死尿激酶溶栓阿司匹林氯吡格雷

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1沈杰,沈卫峰.替罗非班在急性冠脉综合征介入治疗中的应用[J].国际心血管病杂志,2006,33(3):156-159. 被引量：72
2赵明中,黄宏星.CLARITY-TIMI 28和COMMIT/CCS-2研究简介[J].中国医药导刊,2005,7(2):154-154. 被引量：2

二级参考文献19

1[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
2[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.
3[3]Heitzer,T Ollmann,I Koke,K et al.Platelet Glycoprotein Ⅱb/Ⅲa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease[J].Circulation,2003,108 (5):536-541.
4[4]Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95 (1):20-23
5[5]De Luca G,Smit JJ,Ernst N,et al.Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction[J].Thromb Haemost,2005,93 (5):820-823.
6[6]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in STelevation acute myocardial infarction[J].Am J Cardiol,2004,93 (3):280-287.
7[7]Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GP Ⅱb/Ⅲa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients[J].J Invasive Cardiol,2005,17 (6):296-299.
8[8]Roffi M,Chew DP,Mukherjee D,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibition in acute coronary syndromes.Gradient of benefit related to the revascularization strategy[J].Eur Heart J,2002,23 (18):1441-1448.
9[9]Sabatine MS,Morrow DA,Giugliano RP,et al.Implications of upstream glycoprotein Ⅱb/Ⅲa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction:a comparison of the Thrombolysis In Myocardial Infarction (TIMI) ⅢB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial[J].Circulation,2004,109 (7):874-880.
10[10]Marsh JD.Early use of glycoprotein Ⅱb/Ⅲa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes[J].Am J Health Syst Pharm,2002,59 (21 Suppl 7):S15-S26.